Orbus Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3475 Edison Way Ste R, Menlo Park, Calif...Website
www.orbustherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Orbus Therapeutics
Orbus Therapeutics is focused on developing innovative treatments for rare diseases, particularly late-stage brain cancer. The company is currently conducting a clinical trial for eflornithine, aimed at patients with Grade 3 glioma. Orbus is dedicated to improving the health and quality of life for patients facing life-threatening conditions that affect a small percentage of the population. Their commitment is to provide effective therapies where few options exist.Explore more
Orbus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orbus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Orbus Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Orbus Therapeutics is spiking on competitors!
Check if Orbus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Orbus Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Orbus Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Orbus Therapeutics
Orbus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Orbus Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Orbus Therapeutics
Compare insights from companies similar to Orbus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Orbus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orbus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orbus Therapeutics.
Orbus Therapeutics financials insights
Gather financial insights about Orbus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$32.5M
2017
Private Equity
$12.5M
Orbus Therapeutics Tech Stack
A closer look at the technologies used by Orbus Therapeutics
Orbus Therapeutics News & Media
Orbus Therapeutics Highlights Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Benefits in Rare Brain Tumor at Society for Neuro-Oncology (SNO) Annual Meeting
– Updated results based on molecular classification and blinded independent central review demonstrate clinically meaningful survival benefits for patients with recurrent grade 3 astrocytoma who were treated with eflornithine plus standard of care –Orbus Therapeutics Announces Oral Presentation of Updated Results With Blinded Independent Central Review from the Phase 3 STELLAR Clinical Trial at the Society for Neuro-Oncology Annual Meeting
PALO ALTO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 STELLAR trial investigating eflornithine at the Society for Neuro-Oncology (SNO) Annual Meeting being held November 19-23, 2025 in Honolulu, HI. Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain typOrbus Therapeutics Appoints Jason Levin, Co-founder and COO to President
PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of eflornithine to treat malignant glioma, announced that co-founder and current Chief Operating Officer (COO) Jason Levin will become President. Bob Myers, co-founder and Orbus’s President and CEO since 2012, will be stepping down from the role as a day-to-day executive in order to pursue other opportunities in the industCombination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
– OS and PFS Study endpoints met in large subgroup of patients with recurrent astrocytoma, IDH mutant grade 3 as defined by the 2021 WHO CNS Tumor Classification in Orbus Therapeutics’ Phase 3 STELLAR study –
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orbus Therapeutics
Sign Up For FreeTo access detailed company insights
Orbus Therapeutics is focused on developing innovative treatments for rare diseases, particularly late-stage brain cancer. The company is currently conducting a clinical trial for eflornithine, aimed at patients with Grade 3 glioma. Orbus is dedicated to improving the health and quality of life for patients facing life-threatening conditions that a... Read More
